EXPERIENCE YOU CAN TRUST
The firm specializes in complex, commercial litigation. The firm's principal, Joshua H. Grabar, has been involved in some of the largest class actions of the last two decades.
DEDICATION YOU CAN RELY ON
We take pride in providing effective and aggressive representation. Our reputation and history of success speaks for itself and drives lasting client relationships. We are here for you.
LET'S WORK TOGETHER
If you have suffered a financial loss as a result of securities fraud, price-fixing or consumer fraud, you can rest assured that we are on your side. If you are a business seeking to avoid unnecessary legal liability, or reduce the costs of compliance, we are your solution.
latest blog
GRABAR LAW OFFICE FILES ANTITRUST CLASS ACTION ON BEHALF OF MERCHANTS THAT ACCEPT VISA DEBIT CARDS
By Grabar Law |
Grabar Law Office has filed a significant class action lawsuit against Visa Inc., alleging that Visa has systematically abused its market power in the U.S. debit network market. The complaint highlights Visa’s use of a complex and exclusionary strategy that has kept competitors out, restricted innovation, and burdened merchants with exorbitant fees. This has caused…
Read More 
GRABAR LAW OFFICE FILES ANTITRUST CLASS ACTION ON BEHALF OF INDEPENDENT PHARMACIES AGAINST GOODRX AND MAJOR PBMS
By Grabar Law |
Grabar Law Office has filed a class action lawsuit on behalf of independent pharmacies, challenging the anticompetitive practices of GoodRx Holdings, Inc. and four major pharmacy benefit managers (PBMs): CVS Caremark, Express Scripts, MedImpact, and Navitus Health Solutions. The complaint alleges that these PBMs conspired to use GoodRx’s discount card system to artificially lower reimbursement…
Read More 
Grabar Law Office In the News: Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
By Grabar Law |
Current and former officers and directors of dermatological medication maker Verrica Pharmaceuticals Inc. face a shareholder derivative action alleging the company concealed a “litany of issues” with a manufacturer’s facility that ultimately delayed U.S. Food and Drug Administration approval for a skin treatment. In a complaint filed Monday in federal court in Philadelphia, it is…
Read More 
Grabar Law Office In the News: Biotech Execs Face Investor Suit Over Medicare Claims
By Grabar Law |
Executives and directors of biopharmaceutical company Ardelyx have been hit with a shareholder derivative suit in Massachusetts federal court alleging the company misled investors over its intentions and ability to apply for a Medicare reimbursement program for its kidney disease treatment. According to the complaint filed on Friday, Ardelyx obtained approval to distribute Xphozah, an…
Read More